Journal Home
Search for

Volume 36, Issue 5, Pages 494-504 (May 2005)


View previous. 11 of 28 View next.

Differential gene expression in anaplastic lymphoma kinase–positive and anaplastic lymphoma kinase–negative anaplastic large cell lymphomas

Mary Ann Thompson, MD, PhDafCorresponding Author Informationemail address, Jennifer Stumph, MDa, Sarah E. Henrickson, BSg, Andreas Rosenwald, MDg1, QiFu Wang, BSa, Sandy Olson, PhDa, Stephen J. Brandt, MDbcdf, Jeremy Roberts, BSe, Xueqiong Zhang, MSe, Yu Shyr, PhDef, Marsha C. Kinney, MDh

Summary 

Anaplastic large cell lymphoma (ALCL) is an aggressive large T- or null-cell lymphoma. Most ALCLs arising in children and young adults express a constitutively active receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown. This study is the first complementary DNA (cDNA) microarray analysis using RNA extracted from tumor tissue (7 ALK+ ALCLs and 7 ALK− ALCLs) to identify genes differentially expressed or shared between the ALK+ and ALK− tumors. Unsupervised hierarchical clustering using the top 11 most statistically significant discriminator cDNAs correctly grouped all ALK+ and ALK− tumors. Hierarchical clustering analysis using the 44 cDNAs with the greatest differential expression between ALK+ and ALK− RNAs grouped 6 of 7 ALK+ ALCLs together and 1 ALK+ ALCL with the ALK− group. In general, ALK+ tumors overexpress genes encoding signal transduction molecules (SYK, LYN, CDC37) and underexpress transcription factor genes (including HOXC6 and HOX A3) compared with the ALK− group. Cyclin D3 was overexpressed in the ALK+ group and the cell cycle inhibitor p19INK4D was decreased in the ALK− group, suggesting different mechanisms of promoting G1/S transition. Both groups had similar proliferation rates. Genes highly expressed in both ALK− and ALK+ ALCLs included kinases (LCK, protein kinase C, vav2, and NKIAMRE) and antiapoptotic molecules, suggesting possible common pathogenetic mechanisms as well.

a Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

b Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA

c Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

d Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

e Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA

f Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA

g Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

h Department of Pathology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX 78229, USA

Corresponding Author InformationCorresponding author. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232.

 This study was supported by the Vanderbilt University Medical Center Department of Pathology (Nashville, Tenn).

1 Current affiliation: University of Wuerzburg, Wuerzburg, Germany.

PII: S0046-8177(05)00128-0

doi:10.1016/j.humpath.2005.03.004


View previous. 11 of 28 View next.